Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAQX4K)

Drug Name
(S)-tert-butyl 1-oxohexan-2-ylcarbamate Drug Info
Synonyms
CHEMBL96875; ((S)-1-Formyl-pentyl)-carbamic acid tert-butyl ester; BML-244; (S)-tert-butyl 1-oxohexan-2-ylcarbamate; Carbamic acid, [(1S)-1-formylpentyl]-, 1,1-dimethylethyl ester; SCHEMBL3285479; CTK0G6629; OBMGXPJNZKYOQY-VIFPVBQESA-N; ZINC13588585; BDBM50137790; AKOS030572335; tert-butyl(1S)-1-formylpentylcarbamate; CCG-207873; 2(S)-(tert-Butoxycarbonylamino)hexanal; tert-butyl (1S)-1-formylpentylcarbamate; (2S)-2-(tert-Butoxycarbonylamino)hexanal; (S)-2-(tert-butoxycarbonylamino)-5-methylpentanal
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10420833
TTD Drug ID
DMAQX4K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [2]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [3]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [4]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [5]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [5]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [5]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [6]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [5]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [5]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin L (CTSL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KGP94 DM2NZ6K Coagulation defect 3B10.0 Clinical trial [7]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [5]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [5]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [5]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [6]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [5]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [5]
PMID27998201-Compound-7 DMU4QYR Abdominal aortic aneurysm BD50.4 Patented [5]
PMID27998201-Compound-6 DM0LGTY N. A. N. A. Patented [5]
PMID27998201-Compound-1 DM5QH4C Coronavirus infection 1D92 Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [1]
Cathepsin L (CTSL) TT36ETB CATL1_HUMAN Inhibitor [1]

References

1 Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
2 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
4 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
5 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
6 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
7 Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.